Abstract
The Food and Drug Administration has requested that the manufacturer of lorcaserin (Belviq, Belviq XR), a serotonin 2C receptor agonist used as an adjunct to diet and exercise for weight loss, voluntarily withdraw the drug from the U.S. market because of an increased occurrence of cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
